SANTA CLARA, Calif., July 14, 2026
Autonomous Healthcare has achieved a landmark regulatory milestone after the U.S. Food and Drug Administration (FDA) granted De Novo Marketing Authorization for Syncron-E™, an innovative software platform that helps respiratory therapists identify patient-ventilator asynchrony by automatically detecting evidence of ineffective breathing efforts in mechanically ventilated patients. The authorization establishes an entirely new FDA Class II medical device category—Ventilator Waveform Analysis Software—with Syncron-E becoming the first authorized device in this classification. The approval represents a significant advancement in critical care technology, creating a regulatory pathway for future software-based innovations designed to improve intensive care monitoring through artificial intelligence (AI) and advanced waveform analysis. Syncron-E is intended as an adjunctive clinical decision-support tool for respiratory therapists caring for adult patients aged 22 years and older receiving invasive mechanical ventilation. By replacing time-consuming manual waveform review with structured automated analysis, the software has the potential to improve the early recognition of ventilation-related complications while supporting more efficient respiratory care in intensive care units (ICUs).
FDA Establishes New Medical Device Category for Ventilator Software
The FDA De Novo Marketing Authorization represents one of the agency’s most significant regulatory pathways for novel medical technologies, allowing first-of-its-kind devices without existing regulatory classifications to establish new product categories. With this approval, Syncron-E™ becomes the first FDA-authorized Ventilator Waveform Analysis Software, setting the regulatory benchmark that future technologies in this field will follow. The software analyzes previously recorded ventilator waveform data to detect ineffective respiratory efforts, the most common form of patient-ventilator asynchrony, where patients attempt to breathe but the ventilator fails to deliver synchronized assistance. Research has shown that these events occur in nearly half of mechanically ventilated patients and are associated with prolonged ventilation, inspiratory muscle injury, delayed weaning, and poorer clinical outcomes. Because ineffective efforts are often subtle and intermittent, they can easily be missed during routine bedside assessments. Syncron-E addresses this challenge by providing respiratory therapists with automated waveform interpretation supported by multi-site clinical performance data, improving consistency and reducing reliance on manual analysis.
AI-Powered Technology Supports Critical Care Decision-Making
Developed using artificial intelligence, machine learning, and advanced signal analysis, Syncron-E represents the first commercial product within Autonomous Healthcare’s broader strategy to introduce increasingly intelligent automation into critical care medicine. Rather than replacing clinical judgment, the software functions as a clinical decision-support tool, summarizing waveform findings to help respiratory therapists identify patients who may require closer evaluation or ventilator adjustments. Earlier identification of patient-ventilator asynchrony may improve patient comfort, optimize ventilator synchrony, reduce respiratory complications, and support more efficient ventilator management throughout intensive care treatment. By automating one of the most repetitive and technically demanding aspects of respiratory monitoring, the platform also has the potential to reduce clinical workload while allowing healthcare professionals to focus on more complex aspects of patient management.
Advertisement
Autonomous Healthcare Advances Digital Innovation in Intensive Care
The FDA authorization positions Autonomous Healthcare as an emerging innovator in digital critical care technologies, while reinforcing the growing role of software-based medical devices in modern healthcare. The company plans to begin commercial deployment of Syncron-E™ across U.S. healthcare institutions while continuing development of additional AI-enabled automation technologies designed for intensive care and other clinical environments. As hospitals increasingly adopt intelligent software solutions to improve patient monitoring, streamline workflows, and enhance clinical outcomes, the approval of Syncron-E demonstrates how regulatory agencies are embracing next-generation digital health innovations capable of transforming patient care. By creating an entirely new FDA device category, this milestone not only validates Autonomous Healthcare’s technology but also opens the door for future advances in AI-assisted respiratory monitoring, critical care analytics, and automated clinical decision support, ultimately helping clinicians deliver safer, more precise, and more efficient care for critically ill patients.
Source: Autonomous Healthcare press release
